ArticleAmerican journal of respiratory and critical care medicine2009
Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs.
Article in American journal of respiratory and critical care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Neutrophil-related gene expression profile is associated with future paediatric bronchiectasis exacerbations.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Hyperconcentrated mucus in small airways: a mechanistic model for the pathogenesis of paediatric bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Dipeptidyl peptidase-1 inhibitors in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Alpha-defensins increase NTHi binding but not engulfment by the macrophages enhancing airway inflammation in Alpha-1 antitrypsin deficiency.Frontiers in immunology · 2025Article
- Disease Severity and Activity in Bronchiectasis: A Paradigm Shift in Bronchiectasis Management.Tuberculosis and respiratory diseases · 2025Article
- Biomarkers in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- The Association Between Systemic Immune-Inflammation Index at Admission and Readmission in Patients with Bronchiectasis.Journal of inflammation research · 2024Article
- Basic, translational and clinical aspects of bronchiectasis in adults.European respiratory review : an official journal of the European Respiratory Society · 2023Article
- The roles of neutrophils in non-tuberculous mycobacterial pulmonary disease.Annals of clinical microbiology and antimicrobials · 2023Review
- Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes.Mechanisms of ageing and development · 2022Review
- Primary Immun Deficiency in Patients with Non-Cystic Fibrosis Bronchiectasis and Its Relationship with Clinical Parameters.Turkish thoracic journal · 2021Article
- CSF Levels of Elongation Factor Tu Is Associated With Increased Mortality in Malawian Adults WithFrontiers in cellular and infection microbiology · 2020Article
- The biology of pulmonary exacerbations in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Dual effects of human neutrophil peptides in a mouse model of pneumonia and ventilator-induced lung injury.Respiratory research · 2018Article
- Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis.BMC pulmonary medicine · 2018Review
- Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.Cellular & molecular immunology · 2018Review
- Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.American journal of respiratory and critical care medicine · 2017Article
- Bronchiectasis in Children: Current Concepts in Immunology and Microbiology.Frontiers in pediatrics · 2017Review
- Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.Human vaccines & immunotherapeutics · 2016Article
- Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.Annals of the American Thoracic Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
Abstract
rationaleA well-known clinical paradox is that severe bacterial infections persist in the lungs of patients with cystic fibrosis (CF) despite the abundance of polymorphonuclear neutrophils (PMN) and the presence of a high concentration of human neutrophil peptides (HNP), both of which are expected to kill the bacteria but fail to do so. The mechanisms remain unknown.
objectivesThis study examined several possible mechanisms to understand this paradox.
methodsPMN were isolated from sputum and blood of subjects with and without CF or non-CF bronchiectasis for phagocytic assays. HNP isolated from patients with CF were used to stimulate healthy PMN followed by phagocytic tests. MEASUREMENTS AND MAIN
resultsPMN isolated from the sputum of the bronchiectatic patients display defective phagocytosis that correlated with high concentrations of HNP in the lung. When healthy PMN were incubated with HNP, decreased phagocytic capacity was observed in association with depressed surface Fc gamma RIII, actin-filament remodeling, enhanced intracellular Ca(2+), and degranulation. Treatment of PMN with an intracellular Ca(2+) blocker or alpha1-proteinase inhibitor to attenuate the activity of HNP largely prevented the HNP-induced phagocytic deficiency. Intratracheal instillation of HNP in Pallid mice (genetically deficient in alpha1-proteinase inhibitor) resulted in a greater PMN lung infiltration and phagocytic deficiency compared with wild-type mice.
conclusionsHNP or PMN alone exert antimicrobial ability, which was lost as a result of their interaction. These effects of HNP may help explain the clinical paradox seen in patients with inflammatory lung diseases, suggesting HNP as a novel target for clinical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.